vTv Therapeutics (NASDAQ:VTVT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report sent to investors on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price on the stock.

vTv Therapeutics Trading Down 3.0 %

NASDAQ VTVT opened at $19.27 on Friday. The business has a fifty day simple moving average of $15.84 and a 200 day simple moving average of $15.19. vTv Therapeutics has a 12 month low of $8.10 and a 12 month high of $30.99. The firm has a market capitalization of $61.46 million, a P/E ratio of -4.25 and a beta of 0.73.

Institutional Investors Weigh In On vTv Therapeutics

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new position in vTv Therapeutics during the fourth quarter valued at about $25,000. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,327 shares during the last quarter. Finally, FMR LLC bought a new position in shares of vTv Therapeutics during the 3rd quarter valued at approximately $2,402,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.